CoChat

Antitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK

Open access
Tolcher, Anthony W., Khan, Khurum, Ong, Michael, Banerji, Udai, Papadimitrakopoulou, Vassiliki, Gandara, David R., Patnaik, Amita, Baird, Richard D., Olmos, David, Garrett, Christopher R., Skolnik, Jeffrey M., Rubin, Eric H., Smith, Paul D., Huang, Pearl, Learoyd, Maria, Shannon, Keith A., Morosky, Anne, Tetteh, Ernestina, Jou, Ying-Ming, Papadopoulos, Kyriakos P., Moreno, Victor, Kaiser, Brianne, Yap, Timothy A., Yan, Li, de Bono, Johann S. · 2015 · Clinical Cancer Research
Cited by 137

The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.

Abstract

Purpose: KRAS is the most commonly mutated oncogene in human tumors. KRAS-mutant cells may exhibit resistance to the allosteric MEK1/2 inhibitor selumetinib (AZD6244; ARRY-142886) and allosteric AKT inhibitors (such as MK-2206), the combination of which may overcome resistance to both monotherapies. Experimental Design: We conducted a dose/schedule-finding study evaluating MK-2206 and selumetinib in patients with advanced treatment-refractory solid tumors. Recommended dosing schedules were defined as MK-2206 at 135 mg weekly and selumetinib at 100 mg once daily. Results: Grade 3 rash was the most common dose-limiting toxicity (DLT); other DLTs included grade 4 lipase increase, grade 3 stomatitis, diarrhea, and fatigue, and grade 3 and grade 2 retinal pigment epithelium detachment. There were no meaningful pharmacokinetic drug–drug interactions. Clinical antitumor activity included RECIST 1.0–confirmed partial responses in non–small cell lung cancer and low-grade ovarian carcinoma. Conclusion: Responses in KRAS-mutant cancers were generally durable. Clinical cotargeting of MEK and AKT signaling may be an important therapeutic strategy in KRAS-driven human malignancies (Trial NCT number NCT01021748). Clin Cancer Res; 21(4); 739–48. ©2014 AACR.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-14-1901

Cites

10 of 10 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 10 references

Cited by

See all 137

Metadata

Authors
Tolcher, A. W., Khan, K., Ong, M., Banerji, U., Papadimitrakopoulou, V., Gandara, D. R., Patnaik, A., Baird, R. D., Olmos, D., Garrett, C. R., Skolnik, J. M., Rubin, E. H., Smith, P. D., Huang, P., Learoyd, M., Shannon, K. A., Morosky, A., Tetteh, E., Jou, Y.-M., Papadopoulos, K. P., Moreno, V., Kaiser, B., Yap, T. A., Yan, L., & de Bono, J. S.
Venue
Clinical Cancer Research
Published
2015-02-15
Volume
21
Issue
4
Pages
739-748
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2160147190
Cited by
137
References
10
FWCI
5.48
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Antitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-14-1901
The paper
Tolcher, A. W., Khan, K., Ong, M., Banerji, U., Papadimitrakopoulou, V., Gandara, D. R., Patnaik, A., Baird, R. D., Olmos, D., Garrett, C. R., Skolnik, J. M., Rubin, E. H., Smith, P. D., Huang, P., Learoyd, M., Shannon, K. A., Morosky, A., Tetteh, E., Jou, Y.-M., . . . de Bono, J. S. (2015). Antitumor Activity in RAS -Driven Tumors by Blocking AKT and MEK. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-14-1901

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.